Core Insights - Cartesian Therapeutics, Inc. has appointed Carsten Brunn, Ph.D., as Chairman of the Board of Directors, effective October 29, 2025, succeeding Carrie S. Cox [1] - Dr. Brunn is also the President and CEO of the company, and Patrick Zenner, M.B.A., has been named as Lead Independent Director [1] - Carrie S. Cox has played a significant role in advancing the company's lead asset, Descartes-08, and is stepping down to focus on other responsibilities [2] Company Overview - Cartesian Therapeutics is a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases [3] - The lead asset, Descartes-08, is in Phase 3 clinical development for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus, with plans for a Phase 2 basket trial in additional autoimmune indications [3] - The clinical pipeline also includes Descartes-15, an autologous anti-BCMA CAR-T in Phase 1 trial for multiple myeloma [3]